Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 8

1.

Clinical feasibility of (neo)adjuvant taxane-based chemotherapy in older patients: analysis of >4,500 patients from four German randomized breast cancer trials.

Loibl S, von Minckwitz G, Harbeck N, Janni W, Elling D, Kaufmann M, Eggemann H, Nekljudova V, Sommer H, Kiechle M, Kümmel S.

Breast Cancer Res. 2008;10(5):R77. doi: 10.1186/bcr2144. Epub 2008 Sep 16.

2.

[Platinum-free gemcitabine-based combinations: an alternative to conventional chemotherapy of non-small-cell lung cancers?].

Pujol JL, Choma D, Jacot W, Quantin X.

Bull Cancer. 2002 Aug;89 Spec No:S85-90. Review. French.

PMID:
12449036
3.

[Optimal role of docetaxel in adjuvant chemotherapy for early stage HER2-negative breast cancer].

Fattoruso SI, Rossi S, Vici P, Di Filippo F, Botti C, Di Lauro L, Foggi P, Saracca E, Ferranti FR, Visca P, Lopez M.

Clin Ter. 2008 Nov-Dec;159(6):443-7. Review. Italian.

PMID:
19169606
4.

[Gemcitabine and breast cancer].

Besse B, Spano JP.

Bull Cancer. 2002 Aug;89 Spec No:S107-14. Review. French.

PMID:
12449040
5.

[Combinations of platinum salts and gemcitabine in the treatment of non-small-cell lung cancer].

Souquet PJ, Gerinière L.

Bull Cancer. 2002 Aug;89 Spec No:S80-4. Review. French.

6.

Optimizing adjuvant chemotherapy in early-stage breast cancer.

Perez E, Muss HB.

Oncology (Williston Park). 2005 Dec;19(14):1759-67; discussion 1768, 1772-4, 1777-8. Review.

7.

Update on adjuvant chemotherapy for early breast cancer.

Rampurwala MM, Rocque GB, Burkard ME.

Breast Cancer (Auckl). 2014 Oct 8;8:125-33. doi: 10.4137/BCBCR.S9454. eCollection 2014. Review.

8.

Systemic treatment-induced gastrointestinal toxicity: incidence, clinical presentation and management.

Boussios S, Pentheroudakis G, Katsanos K, Pavlidis N.

Ann Gastroenterol. 2012;25(2):106-118. Review.

Supplemental Content

Support Center